Metformin impairs endothelialization after placement of Newer Generation Drug Eluting Stents

Atherosclerosis

Volumn 229, Issue 2, 2013, Pages 385-387

  Habib, Anwer ^a   Karmali, Vinit ^a   Polavarapu, Rohini ^a   Akahori, Hirokuni ^a   Pachura, Kim ^a   Finn, Aloke V ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug eluting stents; Metformin; Vascular endothelium

Indexed keywords

EVEROLIMUS; GLUCOSE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; PACLITAXEL; ZOTAROLIMUS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL FUNCTION; CONTROLLED STUDY; DRUG ELUTING STENT; ENDOTHELIALIZATION; EXPERIMENTAL RABBIT; GLUCOSE BLOOD LEVEL; ILIAC ARTERY STENT; MALE; NONHUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STENT THROMBOSIS; VASCULAR ENDOTHELIUM;

DRUG ELUTING STENTS; METFORMIN; VASCULAR ENDOTHELIUM;

ANGIOPLASTY, BALLOON; ANIMALS; DISEASE MODELS, ANIMAL; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; ILIAC ARTERY; IMMUNOSUPPRESSIVE AGENTS; MALE; METFORMIN; PACLITAXEL; RABBITS; SIROLIMUS; THROMBOSIS; TUBULIN MODULATORS;

EID: 84880446547     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.06.001     Document Type: Article

References (11)

1. Palmerini T., Biondi-Zoccai G., Della Riva D., et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012, 379:1393-1402.
2. Bangalore S., Kumar S., Fusaro M., et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials. BMJ 2012, 345:e5170.
3. Finn A.V., Joner M., Nakazawa G., et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007, 115:2435-2441.
4. Habib A., Karmali V., Polavarapu R., et al. Metformin impairs vascular endothelial recovery after stent placement in the setting of locally eluted Mammalian target of rapamycin inhibitors via s6 kinase-dependent inhibition of cell proliferation. Journal of the American College of Cardiology 2013, 61:971-980.
5. Stefanini G.G., Holmes D.R. Drug-eluting coronary-artery stents. The New England Journal of Medicine 2013, 368:254-265.
6. Joner M., Nakazawa G., Finn A.V., et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. Journal of the American College of Cardiology 2008, 52:333-342.
7. Dowling R.J., Goodwin P.J., Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC Medicine 2011, 9:33.
8. Wessely R., Schomig A., Kastrati A. Sirolimus and paclitaxel on polymer-based drug-eluting stents: similar but different. Journal of the American College of Cardiology 2006, 47:708-714.
9. Gwon H.C., Hahn J.Y., Park K.W., et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 2012, 125:505-513.
10. Stone G.W., Kedhi E., Kereiakes D.J., et al. Differential clinical responses to everolimus-eluting and paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011, 124:893-900.
11. Levine G.N., Bates E.R., Blankenship J.C., et al. ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011, 124:e574-e651.